Drug Resistance, Multiple, Bacterial
"Drug Resistance, Multiple, Bacterial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
| Descriptor ID |
D024901
|
| MeSH Number(s) |
G06.099.225.812 G06.225.347.812 G07.690.773.984.269.347.812 G07.690.773.984.300.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Multiple, Bacterial".
- Biological Sciences [G]
- Microbiological Phenomena [G06]
- Bacterial Physiological Phenomena [G06.099]
- Drug Resistance, Bacterial [G06.099.225]
- Drug Resistance, Multiple, Bacterial [G06.099.225.812]
- Drug Resistance, Microbial [G06.225]
- Drug Resistance, Bacterial [G06.225.347]
- Drug Resistance, Multiple, Bacterial [G06.225.347.812]
- Physiological Phenomena [G07]
- Pharmacological and Toxicological Phenomena [G07.690]
- Pharmacological Phenomena [G07.690.773]
- Drug Resistance [G07.690.773.984]
- Drug Resistance, Microbial [G07.690.773.984.269]
- Drug Resistance, Bacterial [G07.690.773.984.269.347]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.269.347.812]
- Drug Resistance, Multiple [G07.690.773.984.300]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.300.500]
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Multiple, Bacterial".
This graph shows the total number of publications written about "Drug Resistance, Multiple, Bacterial" by people in this website by year, and whether "Drug Resistance, Multiple, Bacterial" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 5 | 2 | 7 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Multiple, Bacterial" by people in Profiles.
-
Acquisition of a genomic resistance island (AbGRI5) from global clone 2 through homologous recombination in a clinical Acinetobacter baumannii isolate. J Antimicrob Chemother. 2021 01 01; 76(1):65-69.
-
Cointegration as a mechanism for the evolution of a KPC-producing multidrug resistance plasmid in Proteus mirabilis. Emerg Microbes Infect. 2020 Dec; 9(1):1206-1218.
-
Antibiotic repurposing: bis-catechol- and mixed ligand (bis-catechol-mono-hydroxamate)-teicoplanin conjugates are active against multidrug resistant Acinetobacter baumannii. J Antibiot (Tokyo). 2020 03; 73(3):152-157.
-
Sepsis 2019: What Surgeons Need to Know. Surg Infect (Larchmt). 2020 Apr; 21(3):195-204.
-
B/O plasmid R16 from 1956 carries an In1-like class 1 integron embedded in a complex region containing parts of the Acinetobacter baumannii AbaR resistance island. Plasmid. 2019 09; 105:102432.
-
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. Am J Health Syst Pharm. 2019 Apr 08; 76(8):501-504.
-
Synthetic sideromycins (skepticism and optimism): selective generation of either broad or narrow spectrum Gram-negative antibiotics. Biometals. 2019 06; 32(3):425-451.
-
"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis. J Clin Microbiol. 2018 09; 56(9).
-
Siderophore Conjugates of Daptomycin are Potent Inhibitors of Carbapenem Resistant Strains of Acinetobacter baumannii. ACS Infect Dis. 2018 10 12; 4(10):1529-1535.
-
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation. Antimicrob Agents Chemother. 2017 12; 61(12).